The sector is awash with mergers and acquisitions but it’s hard to understand what the appeal of Shire/Baxalta is meant to be

The old wisdom said hostile deals don’t work in the world of cutting-edge pharmaceutical research because successful science requires willing partners. In the current bid-a-week biotech bonanza, such niceties can be thrown out of the window, it seems. Shire, the Dublin-based and London-listed outfit, has gone hostile with an all-share $30bn approach to US group Baxalta after being given the cold shoulder by a company spun out of former parent Baxter only last month.

Related: Shire pharmaceutical makes $30bn move for Baxalta

Continue reading…
Source: The Guardian Circular Economy RSS